Modulation of vascular inflammation by PPARs

Drug News and Perspectives

Volumn 16, Issue 2, 2003, Pages 109-116

  Tham, Doris M ^a   Wang, Yi Xin ^b   Rutledge, John C ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b BAYER AG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CELL ADHESION MOLECULE; CHEMOKINE; CYTOKINE; METALLOPROTEINASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR;

ANTIINFLAMMATORY ACTIVITY; ATHEROGENESIS; ATHEROSCLEROSIS; CELL ACTIVATION; CHRONIC INFLAMMATION; ENDOTHELIUM CELL; GENE EXPRESSION REGULATION; INFLAMMATION; MACROPHAGE; MONOCYTE; REVIEW; VASCULAR SMOOTH MUSCLE;

ANGIOTENSIN II; ANIMALS; ARTERIOSCLEROSIS; ARTERITIS; CLINICAL TRIALS; GENE EXPRESSION REGULATION; HUMANS; MACROPHAGES; MONOCYTES; RECEPTORS, CYTOPLASMIC AND NUCLEAR; TRANSCRIPTION FACTORS;

EID: 0037933426     PISSN: 02140934     EISSN: None     Source Type: Journal    
DOI: 10.1358/dnp.2003.16.2.740244     Document Type: Review

References (90)

1. Gulick, T., Cresci, S., Caira, T., Moore, D.D. and Kelly, D.P. The peroxisome proliferator-activated receptor regulates mitochondrial fatty acid oxidative enzyme gene expression. Proc Natl Acad Sci USA 1994, 91: 11012-6.
2. Keller, H., Dreyer, C., Medin, J., Mahfoudi, A., Ozato, K. and Wahli, W. Fatty acids and retinoids control lipid metabolism through activation of peroxisome proliferator-activated receptor-retinoid X receptor heterodimers. Proc Natl Acad Sci USA 1993, 90: 2160-4.
3. Lehmann, J.M., Moore, L.B., Smith-Oliver, T.A., Wilkison, W.O., Willson, T.M. and Kliewer, S.A. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR γ). J Biol Chem 1995, 270: 12953-6.
4. Rosen, E.D., Sarraf, P., Troy, A.E. et al. PPAR gamma is required for the differentiation of adipose tissue in vivo and in vitro. Mol Cell 1999, 4: 611-7.
5. Tontonoz, P., Hu, E. and Spiegelman, B.M. Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipid-activated transcription-factor. Cell 1994, 79: 1147-56.
6. Zhang, B., Berger, J., Zhou, G. et al. Insulin-and mitogen-activated protein kinase-mediated phosphorylation and activation of peroxisome proliferator-activated receptor gamma. J Biol Chem 1996, 271: 31771-4.
7. Marx, N., Schönbeck, U., Lazar, M.A., Libby, P. and Plutzky, J. Peroxisome proliferator-activated receptor gamma activators inhibit gene expression and migration in human vascular smooth muscle cells. Circ Res 1998, 83: 1097-103.
8. Staels, B., Koenig, W., Habib, A. et al. Activation of human aortic smooth-muscle cells is inhibited by PPARalpha but not by PPARgamma activators. Nature 1998, 393: 790-3.
9. Inoue, I., Shino, K., Noji, S., Awata, T. and Katayama, S. Expression of peroxisome proliferator-activated receptor alpha (PPAR alpha) in primary cultures of human vascular endothelial cells. Biochem Biophys Res Commun 1998, 246: 370-4.
10. Marx, N., Sukhova, G.K., Collins, T., Libby, P. and Plutzky, J. PPARalpha activators inhibit cytokine-induced vascular cell adhesion molecule-1 expression in human endothelial cells. Circulation 1999, 99: 3125-31.
11. Chinetti, G., Griglio, S., Antonucci, M. et al. Activation of proliferator-activated receptors alpha and gamma induces apoptosis of human monocyte-derived macrophages. J Biol Chem 1998, 273: 25573-80.
12. Marx, N., Bourcier, T., Sukhova, G.K., Libby, P. and Plutzky, J. PPARgamma activation in human endothelial cells increases plasminogen activator inhibitor type-1 expression: PPARgamma as a potential mediator in vascular disease. Arteriosc Thromb Vasc Biol 1999, 19: 546-51.
13. Jiang, C., Ting, A.T. and Seed, B. PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature 1998, 391: 82-6.
14. Ricote, M., Li, A.C., Willson, T.M., Kelly, C.J. and Glass, C.K. The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature 1998, 391: 79-82.
15. Ricote, M., Huang, J., Fajas, L. et al. Expression of the peroxisome proliferator-activated receptor gamma (PPARgamma) in human atherosclerosis and regulation in macrophages by colony stimulating factors and oxidized low density lipoprotein. Proc Natl Acad Sci USA 1998, 95: 7614-9.
16. Marx, N., Sukhova, G., Murphy, C., Libby, P. and Plutzky, J. Macrophages in human atheroma contain PPARgamma: Differentiation-dependent peroxisomal proliferator-activated receptor gamma (PPARgamma) expression and reduction of MMP-9 activity through PPARgamma activation in mononuclear phagocytes in vitro. Am J Pathol 1998, 153: 17-23.
17. Law, R.E., Goetze, S., Xi, X.P. et al. Expression and function of PPARgamma in rat and human vascular smooth muscle cells. Circulation 2000, 101: 1311-8.
18. Marx, N., Mackman, N., Schonbeck, U. et al. PPARalpha activators inhibit tissue factor expression and activity in human monocytes. Circulation 2001, 103: 213-9.
19. Murao, K., Imachi, H., Momoi, A. et al. Thiazolidinedione inhibits the production of monocyte chemoattractant protein-1 in cytokine-treated human vascular endothelial cells. Febs Letters 1999, 454: 27-30.
20. Pasceri, V., Cheng, J.S., Willerson, J.T., Yeh, E.T. and Chang, J. Modulation of C-reactive protein-mediated monocyte chemoattractant protein-1 induction in human endothelial cells by anti-atherosclerosis drugs. Circulation 2001, 103: 2531-4.
21. Jackson, S.M., Parhami, F., Xi, X.P. et al. Peroxisome proliferator-activated receptor activators target human endothelial cells to inhibit leukocyte-endothelial cell interaction. Arteriosc Thromb Vasc Biol 1999, 19: 2094-104.
22. Pasceri, V., Wu, H.D., Willerson, J.T. and Yeh, E.T. Modulation of vascular inflammation in vitro and in vivo by peroxisome proliferator-activated receptor-gamma activators. Circulation 2000, 101: 235-8.
23. Nawa, T., Nawa, M.T., Cai, Y. et al. Repression of TNF-alpha-induced E-selectin expression by PPAR activators: Involvement of transcriptional repressor LRF-1/ATF3. Biochem Biophys Res Commun 2000, 275: 406-11.
24. Delerive, P., Martin-Nizard, F., Chinetti, G. et al. Peroxisome proliferator-activated receptor activators inhibit thrombin-induced endothelin-1 production in human vascular endothelial cells by inhibiting the activator protein-1 signaling pathway. Circ Res 1999, 85: 394-402.
25. Delerive, P., Furman, C., Teissier, E., Fruchart, J., Duriez, P. and Staels, B. Oxidized phospholipids activate PPARalpha in a phospholipase A2-dependent manner: Febs Letters 2000, 471: 34-8.
26. Lee, H., Shi, W., Tontonoz, P. et al. Role for peroxisome proliferator-activated receptor alpha in oxidized phospholipid-induced synthesis of monocyte chemotactic protein-1 and interleukin-8 by endothelial cells. Circ Res 2000, 87: 516-21.
27. Delerive, P., De Bosscher, K., Besnard, S. et al. Peroxisome proliferator-activated receptor alpha negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NF-kappaB and AP-1. J Biol Chem 1999, 274: 32048-54.
28. Inoue, H., Tanabe, T., Umesono, K. Feedback control of cyclooxygenase-2 expression through PPARgamma. J Biol Chem 2000, 275: 28028-32.
29. Li, M., Pascual, G. and Glass, C.K. Peroxisome proliferator-activated receptor gamma-dependent repression of the inducible nitric oxide synthase gene. Mol Cell Biol 2000, 20: 4699-707.
30. Delerive, P., Gervois, P., Fruchart, J.C. and Staels, B. Induction of IkappaBalpha expression as a mechanism contributing to the anti-inflammatory activities of peroxisome proliferator-activated receptor-alpha activators. J Biol Chem 2000, 275: 36703-7.
31. Neve, B.P., Corseaux, D., Chinetti, G. et al. PPARalpha agonists inhibit tissue factor expression in human monocytes and macrophages. Circ 2001, 103: 207-12.
32. Han, K.H. and Quehenberger, O. Ligands for peroxisome proliferator-activated receptor inhibit monocyte CCR2 expression stimulated by plasma lipoproteins. Trends Cardiovasc Med 2000, 10: 209-16.
33. Maggi, L.B., Jr., Sadeghi, H., Weigand, C., Scarim, A.L., Heitmeier, M.R. and Corbett, J.A. Anti-inflammatory actions of 15-deoxydelta 12,14-prostaglandin J2 and troglitazone: Evidence for heat shock-dependent and -independent inhibition of cytokine-induced inducible nitric oxide synthase expression. Diabetes 2000, 49: 346-55.
34. Ricote, M., Huang, J.T., Welch, J.S. and Glass, C.K. The peroxisome proliferator-activated receptor (PPARgamma) as a regulator of monocyte/macrophage function. J Leukocyte Biol 1999, 66: 733-9.
35. Azuma, Y., Shinohara, M., Wang, P.L. and Ohura, K. 15-Deoxy-delta(12,14)-prostaglandin J(2) inhibits 1L-10 and 1L-12 production by macrophages. Biochem Biophys Res Commun 2001, 283: 344-6.
36. Huang, J.T., Welch, J.S., Ricote, M. et al. Interleukin-4-dependent production of PPAR-gamma ligands in macrophages by 12/15-lipoxygenase. Nature 1999, 400: 378-82.
37. Tontonoz, P., Nagy, L., Alvarez, J.G., Thomazy, V.A. and Evans, R.M. PPARgamma promotes monocyte/macrophage differentiation and uptake of oxidized LDL. Cell 1998, 93: 241-52.
38. Nagy, L., Tontonoz, P., Alvarez, J.G., Chen, H. and Evans, R.M. Oxidized LDL regulates macrophage gene expression through ligand activation of PPARgamma. Cell 1998, 93: 229-40.
39. Moore, K.J., Rosen, E.D., Fitzgerald, M.L. et al. The role of PPAR-Gamma in macrophage differentiation and cholesterol uptake. Nat Med 2001, 7: 41-7.
40. Han, J., Hajjar, D.P., Tauras, J.M., Feng, J., Gotto, A.M. Jr. and Nicholson, A.C. Transforming growth factor-beta 1 (TGF-beta 1) and TGF-beta 2 decrease expression of CD36, the type B scavenger receptor, through mitogen-activated protein kinase phosphorylation of peroxisome proliferator-activated receptor-gamma. J Biol Chem 2000, 275: 1241-6.
41. Chinetti, G., Gbaguidi, F.G., Griglio, S. et al. CLA-1/SR-B1 is expressed in atherosclerotic lesion macrophages and regulated by activators of peroxisome proliferator-activated receptors. Circulation 2000, 101: 2411-7.
42. Chinetti, G., Lestavel, S., Bocher, V. et al. PPAR-alpha and PPAR-gamma activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway. Nat Med 2001, 7: 53-8.
43. Chawla, A., Boisvert, W.A., Lee, C.H. et al. A PPAR gamma-LXR-ABCA1 pathway in macrophages is involved in cholesterol efflux and atherogenesis, Mol Cell 2001, 7: 161-71.
44. Devchand, P.R., Keller, H., Peters, J.M., Vazquez, M., Gonzalez, F.J. and Wahli, W. The PPARalpha-leukotriene B4 pathway to inflammation control. Nature 1996, 384: 39-43.
45. Li, A.C., Brown, K.K., Silvestre, M.J., Willson, T.M., Palinski, W. and Glass, C.K. Peroxisome proliferator-activated receptor gamma ligands inhibit development of atherosclerosis in LDL receptor-deficient mice. J Clin Invest 2000, 106: 523-31.
46. Collins, A.R., Meehan, W.P., Kintscher, U. et al. Troglitazone inhibits formation of early atherosclerotic lesions in diabetic and non-diabetic low density lipoprotein receptor-deficient mice. Arterioscler Thromb Vasc Biol 2001, 21: 365-71.
47. Chen, Z., Ishibashi, S., Perrey, S. et al. Troglitazone inhibits atherosclerosis in apolipoprotein E-knockout mice: Pleiotropic effects on CD36 expression and HDL. Arterioscler Thromb Vasc Biol 2001, 21: 372-7.
48. Takata, Y., Kitami, Y., Yang, Z.H., Nakamura, M., Okura, T. and Hiwada, K. Vascular inflammation is negatively auto-regulated by interaction between CCAAT/ enhancer-binding protein-delta and peroxisome proliferator-activated receptor-gamma. Circ Res 2002, 91: 427-33.
49. Law, R.E., Meehan, W.P., Xi, X.P. et al. Troglitazone inhibits vascular smooth muscle cell growth and intimal hyperplasia. J Clin Invest 1996, 98: 1897-905.
50. Igarashi, M., Takeda, Y., Ishibashi, N. et al. Pioglitazone reduces smooth muscle cell density of rat carotid arterial intima induced by balloon catheterization. Horm Metab Res 1997, 29: 444-9.
51. Yoshimoto, T., Naruse, M., Shizume, H. et al. Vasculo-protective effects of insulin sensitizing agent pioglitazone in neointimal thickening and hypertensive vascular hypertrophy. Atheroscler 1999, 145: 333-40.
52. Ross, R. Atherosclerosis is an inflammatory disease. Am Heart J 1999, 138: S419-20.
53. Wang, Y.X., Martin-McNulty, B., Freay, A.D. et al. Angiotensin II increases urokinase-type plasminogen activator expression and induces aneurysm in the abdominal aorta of apolipoprotein E-deficient mice. Am J Pathol 2001, 159: 1455-64.
54. Brasier, A.R., Jamaluddin, M., Han, Y., Patterson, C. and Runge, M.S. Angiotensin II induces gene transcription through cell-type-dependent effects on the nuclear factor- kappaB (NF-kappaB) transcription factor. Mol Cell Biochem 2000, 212: 155-69.
55. Daugherty, A., Manning, M.W. and Cassis, L.A. Angiotensin II promotes atherosclerotic lesions and aneurysms in apolipoprotein E-deficient mice. J Clin Invest 2000, 105: 1605-12.
56. Keidar, S. Angiotensin, LDL peroxidation and atherosclerosis. Life Sci 1998, 63: 1-11.
57. Keidar, S., Kaplan, M. and Aviram, M. Angiotensin II-modified LDL is taken up by macrophages via the scavenger receptor, leading to cellular cholesterol accumulation. Arterioscler Thromb Vasc Biol 1996, 16: 97-105.
58. Weiss, D., Sorescu, D. and Taylor, W.R. Angiotensin II and atherosclerosis. Am J Cardiol 2001, 87: 25C-32C.
59. Ruiz-Ortega, M., Lorenzo, B., Ruperez, M., Blanco, J. and Egido, J. Systemic infusion of angiotensin II into normal rats activates nuclear factor-kappa B and AP-1 in the kidney - Role of AT(1) and A T(2) receptors. Am J Pathol 2001, 158: 1743-56.
60. Alexander, R.W., Theodore Cooper Memorial Lecture. Hypertension and the pathogenesis of atherosclerosis. Oxidative stress and the mediation of arterial inflammatory response: A new perspective. Hypertension 1995, 25: 155-61.
61. Ross, R. The pathogenesis of atherosclerosis - an update. N Engl J Med 1986, 314: 488-500.
62. Tham, D.M., Martin-McNulty, B., Wang, Y.-X. et al. Angiotensin II is associated with activation of NF-kappa-B-mediated genes and down regulation of PPARs. Physiol Genomics 2002, 11: 21-30.
63. Tham, D.M., Martin-McNulty, B., Wang, Y.-X., Sullivan, M.E. and Rutledge, J.C. PPAR activation down-regulated proinflammatory transcription factors and gene expression in apoE-KO mice treated with Ang II. Submitted 2002.
64. Mendelsohn, M.E. and Karas, R.H. The protective effects of estrogen on the cardiovascular system. N Engl J Med 1999, 340: 1801-11.
65. Tse, J., Martin-McNaulty, B., Halks-Miller, M. et al. Accelerated atherosclerosis and premature calcified cartilaginous metaplasia in the aorta of diabetic male Apo E knockout mice can be prevented by chronic treatment with 17 beta-estradiol. Atherosclerosis 1999, 144: 303-13.
66. Bjarnason, N.H., Haarbo, J., Byrjalsen, I., Alexandersen, P., Kauffman, R.F. and Christiansen, C. Raloxifene and estrogen reduces progression of advanced atherosclerosis - A study in ovariectomized, cholesterol-fed rabbits. Atheroscler 2001, 154: 97-102.
67. Bourassa, P.A., Milos, P.M., Gaynor, B.J., Breslow, J.L. and Aiello, R.J. Estrogen reduces atherosclerotic lesion development in apolipoprotein E-deficient mice. Proc Natl Acad Sci USA 1996, 93: 10022-7.
68. Sulistiyani, Adelman, S.J., Chandrasekaran, A., Jayo, J. and St Clair, R.W. Effect of 17 alpha-dihydroequilin sulfate, a conjugated equine estrogen, and ethynylestradiol on atherosclerosis in cholesterol-fed rabbits. Arterioscler Thromb Vasc Biol 1995, 15: 837-46.
69. Nathan, L., Pervin, S., Singh, R., Rosenfeld, M. and Chaudhuri, G. Estradiol inhibits leukocyte adhesion and transendothelial migration in rabbits in vivo: Possible mechanisms for gender differences in atherosclerosis. Circ Res 1999, 85: 377-85.
70. Pervin, S., Singh, R., Rosenfeld, M.E., Navab, M., Chaudhuri, G. and Nathan, L. Estradiol suppresses MCP-1 expression in vivo: Implications for atherosclerosis. Arterioscler Thromb Vasc Biol 1998, 18: 1575-82.
71. Evans, M.J., Eckert, A., Lai, K., Adelman, S.J. and Hamish, D.C. Reciprocal antagonism between estrogen receptor and NF-kappa B activity in vivo. Circ Res 2001, 89: 823-30.
72. Martin-McNulty, B., Tham, D.M., da Cunha, V. et al. 17Beta-estradiol attenuates development of angiotensin II-induced aortic abdominal aneurysm in apolipoprotein E-deficient mice. Submitted 2002.
73. Khachigian, L.M., Lindner, V., Williams, A.J. and Collins, T. Egr-1-induced endothelial gene expression: A common theme in vascular injury. Science 1996, 271: 1427-31.
74. Silverman, E.S. and Collins, T. Pathways of Egr-1-mediated gene transcription in vascular biology. Am J Pathol 1999, 154: 665-70.
75. Fruebis, J., Gonzalez, V., Silvestre, M. and Palinski, W. Effect of probucol treatment on gene expression of VCAM-1, MCP-1, and M-CSF in the aortic wall of LDL receptor-deficient rabbits during early atherogenesis. Arterioscler Thromb Vasc Biol 1997, 17: 1289-302.
76. Dol, F., Martin, G., Staels, B. et al. Angiotensin AT1 receptor antagonist irbesartan decreases lesion size, chemokine expression, and macrophage accumulation in apolipoprotein E-deficient mice. J Cardiovasc Pharmacol 2001, 38: 395-405.
77. Hernandez-Presa, M.A., Bustos, C., Ortego, M., Tunon, J., Ortega, L. and Egido, J. ACE inhibitor quinapril reduces the arterial expression of NF-kappaB-dependent proinflammatory factors but not of collagen I in a rabbit model of atherosclerosis. Am J Pathol 1998, 153: 1825-37.
78. Sun, Y.P., Zhu, B.Q., Browne, A.E. et al. Comparative effects of ACE inhibitors and an angiotensin receptor blocker on atherosclerosis and vascular function. J Cardiovasc Pharmacol Ther 2001, 6: 175-81.
79. Berkenboom, G., Langer, I., Carpentier, Y., Grosfils, K. and Fontaine, J. Ramipril prevents endothelial dysfunction induced by oxidized low-density lipoproteins: A bradykinin-dependent mechanism. Hypertension 1997, 30: 371-6.
80. da Cunha, V., Tham, D.M., Martin-McNulty, B. et al. Enalapril attenuates angiotensin II-induced atherosclerosis and vascular inflammation. Submitted 2002.
81. Diep, Q.N., El Mabrouk, M., Cohn, J.S. et al. Structure, endothelial function, cell growth, and inflammation in blood vessels of angiotensin II-infused rats: Role of peroxisome proliferator-activated receptor-gamma. Circ 2002, 105: 2296-302.
82. Diabetes Atherosclerosis Intervention Study Investigators. Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: The Diabetes Atherosclerosis Intervention Study, a randomised study. Lancet 2001, 357: 905-10.
83. Ericsson, C.G., Hamsten, A., Nilsson, J., Grip, L., Svane, B. and de Faire, U. Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients. Lancet 1996, 347: 849-53.
84. Frick, M.H., Syvanne, M., Nieminen, M.S. et al. Prevention of the angiographic progression of coronary and vein-graft atherosclerosis by gemfibrozil after coronary bypass surgery in men with low levels of HDL cholesterol. Lopid Coronary Angiography Trial (LOCAT) Study Group. Circulation 1997, 96: 2137-43.
85. Rubins, H.B., Robins, S.J., Collins, D. et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 1999, 341: 410-8.
86. Frick, M.H., Elo, O., Haapa, K. et al. Helsinki Heart Study: Primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 1987, 317: 1237-45.
87. Hahmann, H.W., Bunte, T., Hellwig, N. et al. Progression and regression of minor coronary arterial narrowings by quantitative angiography after fenofibrate therapy. Am J Cardiol 1991, 67: 957-61.
88. Cominacini, L., Garbin, U., Fratta Pasini, A. et al. Troglitazone reduces LDL oxidation and lowers plasma E-selectin concentration in NIDDM patients. Diabetes 1998, 47: 130-3.
89. Minamikawa, J., Tanaka, S., Yamauchi, M., Inoue, D. and Koshiyama, H. Potent inhibitory effect of troglitazone on carotid arterial wall thickness in type 2 diabetes. J Clin Endocrinol Metab 1998, 83: 1818-20.
90. Murakami, T., Mizuno, S., Ohsato, K. et al. Effects of troglitazone on frequency of coronary vasospastic-induced angina pectoris in patients with diabetes mellitus. Am J Cardiol 1999, 84: 92-4, A8.